AD Check - Alzheimer's Disease (p-Tau217) Biomarker Blood Test

US FDA grants breakthrough device designation.
Currently, neither pharmacological nor non-pharmacological treatments can reverse the damage caused by any degree of cognitive impairment. Early intervention is crucial for preventing or delaying the onset of cognitive disorders. The Alzheimer's Disease (p-Tau217) Biomarker Blood Test can identify risks at an early stage. Multiple studies indicate that the only there is an opportunity to slow down and improve the condition during the early stages of cognitive impairment (MCI). This test helps in preventing or delaying the onset of cognitive disorders before the condition progresses.

What is p-Tau?
Phosphorylated-Tau (p-Tau) is a specific plasma biomarker that reflects Alzheimer’s Disease (AD) pathology, showing a significant increase in patients with AD. This rise occurs in parallel with extracellular Aβ plaque deposition, a hallmark feature of the disease.

Among Tau blood biomarkers, p-Tau217 has demonstrated exceptional accuracy in distinguishing AD from other neurodegenerative disorders and identifying patients with Mild Cognitive Impairment (MCI). Its performance is comparable to advanced diagnostic tools like PET imaging and cerebrospinal fluid (CSF) biomarkers, offering reproducible cut-off values across different cohorts. Additionally, p-Tau217 is capable of tracking longitudinal changes, even in the preclinical stages of AD, making it a valuable tool for early detection and disease monitoring.

Testing Process
Blood Sample: Only a 3ml blood draw from a vein is required.

Fasting Requirement: No fasting is necessary before the blood draw.

Important Notes: For patients with chronic kidney disease-related renal impairment, results may show elevated levels. Interpretation of results should be combined with other clinical test results for analysis.

TAT: Results analysis requires 5 to 10 business days